Voya Financial, Inc. (VOYA) Trades at $51.32 After Triangle; Barclays Plc Decreased Glaxosmithkline Plc (GSK) Stake

Voya Financial, Inc. (NYSE:VOYA) Logo

Voya Financial, Inc. (VOYA) formed triangle with $48.75 target or 5.00% below today’s $51.32 share price. Voya Financial, Inc. (VOYA) has $8.66 billion valuation. The stock decreased 0.74% or $0.38 during the last trading session, reaching $51.32. About 2.28M shares traded or 13.95% up from the average. Voya Financial, Inc. (NYSE:VOYA) has risen 53.04% since June 18, 2017 and is uptrending. It has outperformed by 40.47% the S&P500. Some Historical VOYA News: ; 08/03/2018 – S&PGR Asgns Voya CLO 2018-1 Ltd.’s Nts Prelim Rtgs; 23/04/2018 – VOYA FINANCIAL INC – AS OF MARCH 31, 2018, AUM OF COMPANY’S IM SEGMENT WAS $222 BLN – SEC FILING; 11/05/2018 – VOYA FINANCIAL INC – PEN-CAL WILL BECOME PART OF VOYA’S RETIREMENT BUSINESS OPERATING UNIT; 15/03/2018 – Voya Infrastructure, Industrials and Materials Fund Declares Quarterly Distribution; 21/04/2018 – DJ Voya Financial Inc, Inst Holders, 1Q 2018 (VOYA); 30/04/2018 – Voya Real Estate Adds Healthcare Realty, Buys More SL Green; 30/04/2018 – Voya Global Real Estate Adds Gaming and Leisure; 23/03/2018 – S&PGR Assigns 7 Prelim Rtgs To Voya CLO 2013-2 Ltd; 18/04/2018 – Fitch Rates Voya CLO 2014-1 Ltd./LLC; Publishes New Issue Report; 01/05/2018 – VOYA FINL 1Q ADJ. OPER EPS $0.77, EST. 85C

Barclays Plc decreased Glaxosmithkline Plc (GSK) stake by 40.4% reported in 2018Q1 SEC filing. Barclays Plc sold 47,636 shares as Glaxosmithkline Plc (GSK)’s stock rose 7.70%. The Barclays Plc holds 70,264 shares with $2.75M value, down from 117,900 last quarter. Glaxosmithkline Plc now has $102.33B valuation. The stock decreased 1.19% or $0.5 during the last trading session, reaching $41.44. About 2.44M shares traded. GlaxoSmithKline plc (NYSE:GSK) has declined 6.39% since June 18, 2017 and is downtrending. It has underperformed by 18.96% the S&P500. Some Historical GSK News: ; 24/05/2018 – GSK PHARMA INDIA 4Q DIV/SHR 35 RUPEES; 27/03/2018 – Nestle, other food groups likely suitors for GSK’s Horlicks; 25/04/2018 – THERAVANCE BIOPHARMA INC – EXPANDED APPROVAL IN U.S. ALLOWS TRELEGY ELLIPTA TO BE USED AS A TREATMENT FOR A BROADER POPULATION OF COPD PATIENTS; 23/03/2018 – GLAXOSMITHKLINE PLC GSK.L – VIIV HEALTHCARE GAINS CHMP POSITIVE OPINION FOR JULUCA (DOLUTEGRAVIR/RILPIVIRINE) IN EUROPE; 21/03/2018 – GlaxoSmithKline has lagged rivals like Novartis and Merck in producing multibillion-dollar blockbusters; 27/03/2018 – NOVARTIS AG NOVN.S – THE FOUR DIRECTORS WILL STEP DOWN IN CONNECTION WITH COMPLETION OF TRANSACTION; 22/03/2018 – GSK advances in Pfizer consumer health auction as Reckitt quits; 27/03/2018 – CNBC Wires: Nestle, other food groups likely suitors for GSK’s Horlicks; 25/04/2018 – GLAXOSMITHKLINE GSK.L CEO SAYS NO.1 PRIORITY IS ON INVESTING IN PHARMA R&D, INCLUDING BRINGING IN EARLY-STAGE ASSETS; 16/05/2018 – UK lawmakers call for post-Brexit pharmaceutical deal with EU

Since February 21, 2018, it had 1 insider purchase, and 2 insider sales for $369,684 activity. $698,439 worth of Voya Financial, Inc. (NYSE:VOYA) was bought by Nelson Charles P on Tuesday, May 1. $45,439 worth of Voya Financial, Inc. (NYSE:VOYA) was sold by SILVA KEVIN D on Wednesday, February 21.

Analysts await Voya Financial, Inc. (NYSE:VOYA) to report earnings on August, 7. They expect $1.09 earnings per share, up 62.69% or $0.42 from last year’s $0.67 per share. VOYA’s profit will be $184.02M for 11.77 P/E if the $1.09 EPS becomes a reality. After $0.77 actual earnings per share reported by Voya Financial, Inc. for the previous quarter, Wall Street now forecasts 41.56% EPS growth.

Investors sentiment decreased to 0.86 in 2018 Q1. Its down 0.12, from 0.98 in 2017Q4. It dived, as 35 investors sold Voya Financial, Inc. shares while 132 reduced holdings. 59 funds opened positions while 84 raised stakes. 174.45 million shares or 2.58% less from 179.07 million shares in 2017Q4 were reported. Amp Capital Invsts Limited invested in 0.05% or 171,910 shares. Ajo Lp has 1.98M shares. Asset Mngmt One Limited has invested 0.03% in Voya Financial, Inc. (NYSE:VOYA). Tcw Group accumulated 0.01% or 14,504 shares. Viking Ltd Partnership reported 0.52% stake. Prudential owns 0% invested in Voya Financial, Inc. (NYSE:VOYA) for 11,000 shares. Gam Holdings Ag invested in 11,163 shares. Pnc Fincl Group holds 0% or 8,250 shares in its portfolio. Tillar invested in 2.25% or 76,338 shares. D E Shaw Incorporated reported 1.86 million shares stake. Legal & General Grp Incorporated Plc invested in 0.03% or 848,971 shares. Moreover, Cwm Ltd Liability Com has 0% invested in Voya Financial, Inc. (NYSE:VOYA) for 200 shares. Invesco Limited holds 6.59 million shares. Massmutual Communications Fsb Adv reported 80 shares. Morgan Stanley accumulated 776,727 shares.

Among 18 analysts covering Voya Financial (NYSE:VOYA), 14 have Buy rating, 1 Sell and 3 Hold. Therefore 78% are positive. Voya Financial had 50 analyst reports since August 26, 2015 according to SRatingsIntel. As per Monday, November 13, the company rating was upgraded by Sandler O’Neill. The firm earned “Buy” rating on Wednesday, November 1 by RBC Capital Markets. RBC Capital Markets maintained the stock with “Buy” rating in Monday, October 9 report. The stock of Voya Financial, Inc. (NYSE:VOYA) has “Buy” rating given on Tuesday, April 17 by Deutsche Bank. The firm has “Underweight” rating by JP Morgan given on Tuesday, January 3. As per Wednesday, November 9, the company rating was downgraded by RBC Capital Markets. The company was maintained on Friday, November 10 by Keefe Bruyette & Woods. On Wednesday, February 14 the stock rating was maintained by RBC Capital Markets with “Buy”. As per Friday, July 15, the company rating was downgraded by Goldman Sachs. The rating was maintained by Keefe Bruyette & Woods with “Buy” on Thursday, August 31.

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 9 have Buy rating, 1 Sell and 8 Hold. Therefore 50% are positive. GlaxoSmithKline had 29 analyst reports since September 8, 2015 according to SRatingsIntel. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Buy” rating given on Wednesday, December 9 by Bank of America. The company was maintained on Wednesday, February 14 by Cowen & Co. The company was upgraded on Monday, November 27 by UBS. The stock of GlaxoSmithKline plc (NYSE:GSK) earned “Overweight” rating by Piperjaffray on Friday, September 23. BNP Paribas downgraded the stock to “Underperform” rating in Wednesday, September 14 report. J P Morgan Chase Co maintained the shares of GSK in report on Friday, June 16 with “Neutral” rating. The company was upgraded on Friday, May 26 by Berenberg. The stock has “Neutral” rating by BNP Paribas on Tuesday, September 15. The rating was initiated by Cantor Fitzgerald on Friday, February 26 with “Hold”. Bank of America upgraded the stock to “Neutral” rating in Tuesday, September 8 report.

Barclays Plc increased International Business Machs (NYSE:IBM) stake by 2.25 million shares to 2.43 million valued at $372.52 million in 2018Q1. It also upped Nuance Communications Inc (Call) (NASDAQ:NUAN) stake by 314,200 shares and now owns 330,800 shares. Hawaiian Holdings Inc (NASDAQ:HA) was raised too.

Voya Financial, Inc. (NYSE:VOYA) Institutional Positions Chart